Previous 10 | Next 10 |
Potential merger to create new industry leader. Vancouver, British Columbia--(Newsfile Corp. - October 25, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) (" MYND " or the " Company "), a pioneering biopharmaceutical research and development company dedicated to revolutionizing treatment...
MYND Life Sciences was formed to commercialize proprietary biomarker diagnostic tests and novel therapeutics for patients suffering from MDD, TRD and other neuro-inflammatory disorders Vancouver, British Columbia--(Newsfile Corp. - September 11, 2023) - MYND Life Sciences Inc. (CSE: MYND) (OTCQ...
Vancouver, British Columbia--(Newsfile Corp. - May 9, 2023) - MYND Life Sciences ( CSE: MYND ) ( OTCQB: MYNDF ) (" MYND " or the " Company "), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological di...
Vancouver, British Columbia--(Newsfile Corp. - April 12, 2023) - MYND Life Sciences (CSE: MYND ) (OTCQB: MYNDF ) (" MYND " or the " Company "), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological...
Global expansion as MYND executes non-binding MOU with German based Oxygen Handel. Vancouver, British Columbia--(Newsfile Corp. - March 28, 2023) - MYND Life Sciences (CSE: MYND ) (OTCQB: MYNDF ) (" MYND " or the " Company "), a biopharmaceutical research and development company creating inn...
Vancouver, British Columbia--(Newsfile Corp. - March 1, 2023) - MYND Life Sciences Inc. (CSE: MYND) ("MYND" or the "Company") announces that it has been advised by its external auditors (the "Auditors") that they will not be in a position to complete their work on the Company's annual consolida...
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2023) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ( " MYND " or the " Company "), a biopharmaceutical research and development company creating innovated and precision medicines for patients with relentless neurological disea...
TORRANCE Calif. , July 17, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, and MYnd Analytics, Inc. announced today that they have completed the previously announced merger transaction, following stockholder approval by both companies ...
Gainers: Nautilus (NYSE: NLS ) +21% . Francesca's Holdings (NASDAQ: FRAN ) +20% . Anixa Biosciences (NASDAQ: ANIX ) +19% . AVROBIO (NASDAQ: AVRO ) +19% . Rekor Systems (REKR) +18% . Seattle Genetics (NASDAQ: SGEN ) +18% . Hill International (NYSE: HIL ) +18% . scPharmaceutical...
MYnd Analytics ( MYND -4% ) announces that its shareholders and shareholders of Emmaus Life Sciences have voted overwhelmingly (96% and 99.98%, respectively) in favor of the merger . More news on: MYnd Analytics, Inc., Healthcare stocks news, Merger & acquisition news, Read mo...
News, Short Squeeze, Breakout and More Instantly...
Mynd Life Sciences Inc Com Company Name:
MYND Stock Symbol:
NASDAQ Market:
Mynd Life Sciences Inc Com Website:
Promethean's ActivPanel LX is honored by the 2024 EdTech Breakthrough Awards PR Newswire The company's flexible, secure, and affordable interactive display receives the prestigious "Classroom Tech Solution of the Year" award SEATTLE , June 6, 2024 /PRNews...
Mynd Announces Fiscal Year 2023 Results PR Newswire Delivers Revenue of $413.6 Million and Successfully Completes Transformational Merger Transaction SEATTLE , March 27, 2024 /PRNewswire/ -- Mynd.ai, Inc. (the "Company" or "...
Promethean wins three Tech & Learning Awards of Excellence for 2023 Promethean wins three Tech & Learning Awards of Excellence for 2023 PR Newswire The company was recognized for its ActivPanel LX display, OPS-A computing module, and Explain Everything Advanced les...